Title:
ANTIBODY-MULTIDRUG CONJUGATE PRECURSOR AND SYNTHETIC INTERMEDIATE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/234427
Kind Code:
A1
Abstract:
Provided is a conjugate precursor for obtaining a more useful antitumor agent by further developing a conventional antibody-drug conjugate. Provided are: an antibody-multidrug conjugate precursor represented by general formula (I) (in the formula, the symbols have the meanings as defined in the specification) or a salt thereof; and a synthetic intermediate thereof or a salt thereof.
Inventors:
TSUZAKI YASUNORI (JP)
MIZUNO GEN (JP)
KASHIWAGI TAKAMASA (JP)
TANAKA MASAYUKI (JP)
SHIMIZU HAYATO (JP)
NONOUCHI SHINPEI (JP)
MATSUSHITA TAKASHI (JP)
KIMURA TOMIO (JP)
MIZUNO GEN (JP)
KASHIWAGI TAKAMASA (JP)
TANAKA MASAYUKI (JP)
SHIMIZU HAYATO (JP)
NONOUCHI SHINPEI (JP)
MATSUSHITA TAKASHI (JP)
KIMURA TOMIO (JP)
Application Number:
PCT/JP2023/021638
Publication Date:
December 07, 2023
Filing Date:
June 02, 2023
Export Citation:
Assignee:
UBE CORP (JP)
International Classes:
A61K47/68; A61K31/337; A61K31/357; A61K31/407; A61K31/4375; A61K31/4745; A61K31/475; A61K31/513; A61K31/537; A61K31/5513; A61K31/5517; A61K31/675; A61K31/7034; A61K31/7036; A61K31/706; A61K45/00; A61P35/00
Domestic Patent References:
| WO2014061277A1 | 2014-04-24 | |||
| WO2020236817A2 | 2020-11-26 | |||
| WO2022115451A1 | 2022-06-02 |
Foreign References:
| JP2013136590A | 2013-07-11 |
Other References:
XIAO, DIAN ET AL.: "A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate", THERANOSTICS, vol. 11, no. 6, 2021, pages 2550 - 2563, XP093087170, DOI: 10.7150/thno.51232
SU, ZHENG ET AL.: "Antibody-drug conjugates: Recent advances in linker chemistry", ACTA PHARMACEUTICA SINICA B, vol. 11, no. 12, 2021, pages 3889 - 3907, XP093087740, DOI: 10.1016/j.apsb.2021.03.042
LIU, LIANQI ET AL.: "S ynthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates", DRUG DELIVERY, vol. 28, no. 1, 2021, pages 2603 - 2617, XP093087176, DOI: 10.1080/10717544.2021.2008053
LAU, ULAND Y ET AL.: "Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins", MOL. PHARMACEUTICS, vol. 15, no. 9, 2018, pages 4063 - 4072, XP055618626, DOI: 10.1021/acs.molpharmaceut.8b00477
MANABE, SHINO: "Development and Current Status of Antibody-drug conjugate (ADC", DRUG DELIVERY SYSTEM, vol. 34, no. 1, 2019, pages 10 - 21, XP093087000
KERN, C. J ET AL.: "Novel phosphate modified Cathepsin B linkers: Improving aqueous solubility and enhancing payload scope of ADCs", BIOCONJUGATE CHEM, vol. 27, no. 9, 2016, pages 2081 - 2088, XP055557206, DOI: 10.1021/acs.bioconjchem.6b00337
SU, ZHENG ET AL.: "Antibody-drug conjugates: Recent advances in linker chemistry", ACTA PHARMACEUTICA SINICA B, vol. 11, no. 12, 2021, pages 3889 - 3907, XP093087740, DOI: 10.1016/j.apsb.2021.03.042
LIU, LIANQI ET AL.: "S ynthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates", DRUG DELIVERY, vol. 28, no. 1, 2021, pages 2603 - 2617, XP093087176, DOI: 10.1080/10717544.2021.2008053
LAU, ULAND Y ET AL.: "Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins", MOL. PHARMACEUTICS, vol. 15, no. 9, 2018, pages 4063 - 4072, XP055618626, DOI: 10.1021/acs.molpharmaceut.8b00477
MANABE, SHINO: "Development and Current Status of Antibody-drug conjugate (ADC", DRUG DELIVERY SYSTEM, vol. 34, no. 1, 2019, pages 10 - 21, XP093087000
KERN, C. J ET AL.: "Novel phosphate modified Cathepsin B linkers: Improving aqueous solubility and enhancing payload scope of ADCs", BIOCONJUGATE CHEM, vol. 27, no. 9, 2016, pages 2081 - 2088, XP055557206, DOI: 10.1021/acs.bioconjchem.6b00337
Attorney, Agent or Firm:
TSUDA, Osamu (JP)
Download PDF: